ليتروزول تيڤع

Država: Izrael

Jezik: arapski

Izvor: Ministry of Health

Aktivni sastojci:

LETROZOLE 2.5 MG

Dostupno od:

TEVA PHARMACEUTICAL INDUST.LTD

ATC koda:

L02BG04

Farmaceutski oblik:

TABLETS

Administracija rute:

PER OS

Proizveden od:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Terapijska grupa:

LETROZOLE

Terapijske indikacije:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Datum autorizacije:

2010-01-01